Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Bhattacharya et al.
, Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
, medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
risk of case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%), NNT 3.2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bhattacharya et al., 9 Jun 2020, retrospective, India, preprint, 7 authors.
Abstract: International Journal of Research in Medical Sciences
Bhattacharya R et al. Int J Res Med Sci. 2020 Oct;8(10):3518-3522
pISSN 2320-6071 | eISSN 2320-6012
Original Research Article
The beneficial role of N-acetylcysteine as an adjunctive drug in
treatment of COVID-19 patients in a tertiary care hospital in India:
an observational study
Raja Bhattacharya1, Maitry Mondal1, Subhendu Bikash Naiya1, Lamsaka Lyngdoh1,
Rishav Mukherjee1*, Prabhat K. Singh2
Department of Medicine, Medical College and Hospital, Kolkata, West Bengal, India
Marwari Relief Society, Kolkata, West Bengal, India
Received: 25 August 2020
Revised: 09 September 2020
Accepted: 10 September 2020
Dr. Rishav Mukherjee,
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial
use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: N-acetyl cysteine, a mucolytic agent, demonstrates free radical scavenging and anti-inflammatory
properties, and prevents endothelial dysfunction by inhibition of NF-KB and formation of no adducts. This has a
potential role to tackle cytokine storms, endothelial dysfunction and prothrombotic state observed in COVID-19
manifestations like ARDS and Multi organ dysfunction.
Methods: Institution based descriptive cross sectional study, 164 patients from laboratory confirmed RT PCR
positive COVID-19 patients, in the study period from 27th May 2020 to 10th August 2020, were assessed, in medical
college Kolkata, a dedicated COVID-19 care facility.
Results: It was observed that moderate-severe patients who received N-acetyl cysteine along with standard therapy
had average hospital stay duration of 12 days, higher rate of discharge, average duration of oxygen therapy of 8 days,
less number of deaths and reduced transfer to critical care facilities.
Conclusions: N-acetyl cysteine can be considered as an adjunctive therapy with standard protocol driven care, due to
its beneficial anti-inflammatory and free radical scavenging properties.
Keywords: COVID-19, N-acetyl cysteine, Free radical scavenger, Anti-inflammatory
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.